Julie M. Caldwell

Jun 26, 2024 | scienceblog.cincinnatichildrens.org | Marc E. Rothenberg |Margaret Collins |Julie M. Caldwell

Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn’t make patients feel better and doesn’t reverse tissue damage in their throats. Meanwhile, data shows that a different drug that had previously been approved for use in adults and teens with EoE is also safe and effective for children under 12 who weigh at least 15 kg (about 33 pounds).

Oct 29, 2023 | biorxiv.org | Simin Zhang |Julie M. Caldwell |Mark Rochman |Margaret Collins

AbstractBackground: Eosinophilic esophagitis (EoE) is diagnosed and monitored using esophageal eosinophil levels; however, EoE also exhibits a marked, understudied esophageal mastocytosis. Objective: Using machine learning, we localized and characterized esophageal mast cells to decipher their potential role in disease pathology.

Feb 3, 2023 | jacionline.org | Julie M. Caldwell |Adina Ballaban |Jie Li |Bristol Myers Squibb

The molecular pathogenesis of the type 2 inflammatory disease eosinophilic esophagitis (EoE) is largely driven by IL-13-mediated effects. A humanized monoclonal anti-IL-13 antibody (cendakimab) lowered esophageal eosinophils and improved outcomes in clinical trials. We aimed to determine how systemic cendakimab administration impacted local esophageal gene expression in a substudy of a double-blind, placebo-controlled phase 2 trial (NCT02098473).